Evidence map›Paper›PMID 29097800›Full record

ArticleScientific reports2017

HIF-1α- Targeting Acriflavine Provides Long Term Survival and Radiological Tumor Response in Brain Cancer Therapy.

Antonella Mangraviti, Tula Raghavan, Francesco Volpin, Nicolas Skuli, David Gullotti, Jinyuan Zhou, Laura Asnaghi, Eric Sankey, Ann Liu, Yuan Wang and 11 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 87 citations in OpenAlex.

  1. Review
  2. Review
  3. Enhancing the efficacy of VEGF inhibitors by co-inhibition of HIF in the treatment of glioblastoma.Apoptosis : an international journal on programmed cell death · 2026
    Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Optimizing CAR-T Therapy for Glioblastoma.Molecular diagnosis & therapy · 2023
    Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 3 institutions in 3 countries.

Antonella MangravitiDepartment of Neurosurgery, Johns Hopkins University, Baltimore, MD, USA.
Tula RaghavanDepartment of Neurosurgery, Johns Hopkins University, Baltimore, MD, USA.
Francesco VolpinDepartment of Neurosurgery, Johns Hopkins University, Baltimore, MD, USA.
Nicolas SkuliDepartment of Neurosurgery, Johns Hopkins University, Baltimore, MD, USA.
David GullottiDepartment of Neurosurgery, Johns Hopkins University, Baltimore, MD, USA.
Jinyuan ZhouDepartment of Radiology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Laura AsnaghiDepartment of Pathology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Eric SankeyDepartment of Neurosurgery, Johns Hopkins University, Baltimore, MD, USA.ORCID 0000-0003-1400-0434
Ann LiuDepartment of Neurosurgery, Johns Hopkins University, Baltimore, MD, USA.
Yuan WangDepartment of Neurosurgery, Johns Hopkins University, Baltimore, MD, USA.
Dong-Hoon LeeDepartment of Radiology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Noah GorelickDepartment of Neurosurgery, Johns Hopkins University, Baltimore, MD, USA.
Riccardo SerraDepartment of Neurosurgery, Johns Hopkins University, Baltimore, MD, USA.
Michael PetersDepartment of Neurosurgery, Johns Hopkins University, Baltimore, MD, USA.
Destiny SchrieferDepartment of Neurosurgery, Johns Hopkins University, Baltimore, MD, USA.
Fabien DelaspreMcKusick-Nathans Institute for Genetic Medicine, Johns Hopkins University, Baltimore, MD, USA.ORCID 0000-0001-7815-5537
Fausto J RodriguezDepartment of Pathology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Charles G EberhartDepartment of Pathology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Henry BremDepartment of Neurosurgery, Johns Hopkins University, Baltimore, MD, USA.
Alessandro OliviDepartment of Neurosurgery, Johns Hopkins University, Baltimore, MD, USA.
Betty TylerDepartment of Neurosurgery, Johns Hopkins University, Baltimore, MD, USA. btyler@jhmi.edu.ORCID 0000-0001-9800-6969
Johns Hopkins University · USThe University of Sydney · AUUniversità Cattolica del Sacro Cuore · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor progression, limited efficacy of current standard treatments, and the rise in patient mortality are associated with gene expression caused by the synergistic action of intratumoral hypoxia and HIF-1α activation. For this reason, recent investigations have focused on HIF-targeting therapeutic agents, with encouraging preclinical and clinical results in solid tumors. Here we describe the efficacy of a HIF-1α inhibitor, Acriflavine, and demonstrate its potency against brain cancer. This safe antibacterial dye induces cell death and apoptosis in several glioma cell lines, targets HIF-1α-mediated pathways, and decreases the level of PGK1, VEGF and HIF-1α in vitro and in vivo. Administered locally via biodegradable polymers, Acriflavine provides significant benefits in survival resulting in nearly 100% long term survival, confirmed by MRI and histological analyses. This study reports preclinical evidence that this safe, small molecule can contribute to brain tumor therapy and highlights the significance of HIF-1α-targeting molecules.

Indexed as

AcriflavineAnimalsApoptosisBrainBrain NeoplasmsCell Line, TumorDrug Delivery SystemsFluorescent DyesGliomaHumansHypoxia-Inducible Factor 1, alpha SubunitRats, Inbred F344AcriflavineFluorescent DyesHypoxia-Inducible Factor 1, alpha Subunit

Identifiers

PMID29097800
PMCPMC5668269
OpenAlexW2766320516

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.